Hackers Steal Passwords From UK's NHS With Sneaky Malware Tool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Talking therapy for depression and anxiety ‘less effective for young adults'
NHS talking therapies for depression and anxiety appear to be less effective for young adults, according to new analysis. Younger people may find it 'harder to navigate services set up for adults' – with attendance to therapy sessions hampered by stressful life events in the late teens and early 20s, experts suggest. Researchers warned there is an 'urgent need' to ensure the best possible mental healthcare for people aged 16-25 amid rising rates of mental health conditions. NHS talking therapy for conditions like anxiety and depression can include cognitive behavioural therapy (CBT), counselling, and guided self-help using workbooks or online courses. To explore ways in which services could be tailored to younger people, experts from University College London (UCL) analysed data from 1.5 million people who had attended NHS talking therapies in England between 2015 and 2019, including more than 309,758 people aged between 16 and 24. Using self-reported scores from questionnaires taken before and after treatment, researchers found younger adults were 25% less likely to meet the threshold for reliable recovery after having talking therapy. They were also 17% less likely to meet criteria for reliable improvement when compared to those aged 25-65. Professor Argyris Stringaris, of UCL psychiatry, suggested people aged 16-24 may find it harder to regularly attend therapy sessions. He said: 'Young people may find it harder to navigate services which have been set up for adults, and are more likely to miss sessions or stop attending altogether. 'Additionally, the late teens and early 20s are a point of transition for many people, which can involve plenty of stressful life events and changes that may make it more difficult to consistently attend. 'Working together with young people should help optimise the content of treatment and the ways in which it is delivered. 'Finally, young people may suffer from depression and anxiety problems that may differ somehow in their causes from those affecting adults; early onset depression could have different causes and may require different approaches to treatment. This is an area that requires a lot of new basic and clinical research.' Researchers said the findings, published in Lancet Psychiatry, suggest future studies should consider tailoring mental health services to young people. Dr Rob Saunders, of UCL psychology and language sciences, said: 'Talking therapy is an effective treatment for depression and anxiety disorders, and particularly tends to be preferred to pharmacological treatment by younger adults. 'Our analysis shows that talking therapies offered by the NHS are effective for younger adults, but as they are more effective for working-age adults, we believe there is work to be done to improve services for young adults. 'Rates of depression and anxiety in young adults are rising, so there is an urgent need to ensure we are offering them the best possible mental health care.' The latest Adult Psychiatric Morbidity Survey, published in June, found more than a quarter of people aged 16-24 reported having so-called 'common mental health conditions', which include generalised anxiety disorder, depressive episodes, phobias, obsessive compulsive disorder (OCD) and panic disorder. The figure was up from 17.5% in 2007. An NHS spokesperson said: 'This study finds talking therapy is still helpful for young people and so we would urge them to come forward for care with our world-leading talking therapies service which provides evidence-based mental health support to more than a million people a year, with nine in 10 patients receiving support within six weeks.' Olly Parker, head of external affairs and research at the charity YoungMinds, said: 'Growing up today is incredibly tough. 'Many young people are experiencing multiple pressures which impact their mental health, including poverty, inequality, intense academic pressure, and the online world. It's no wonder so many are struggling. 'We know many young people face long waits for mental health support and become more unwell while waiting, which can lead to needing more urgent care. We need to take an evidence-led approach to getting support right, ensuring young people are involved in choosing the treatments that work best for them. 'These findings must serve as another wake-up call to Government that urgent action is needed to reverse the decline in young people's mental health. This looks like a cross-government response that asks why so many young people are struggling, with radical solutions to address these root causes of poor mental health.'
Yahoo
2 hours ago
- Yahoo
Crackdown on cosmetic surgery ‘cowboys' over botched Brazilian butt lifts and Botox
Ministers want to clamp down on 'cowboy' cosmetic procedures including Botox and Brazilian butt lifts after a string of horror incidents which left customers dead or with catastrophic damage. Officials said the industry had been blighted by 'dodgy practitioners and procedures', with some patients 'maimed' during botched treatments. It follows the case of mother-of-five, Alice Webb, who is thought to be the first person to have died following a non-surgical liquid Brazilian butt lift (BBL) procedure at a UK clinic. The Department of Health and Social Care (DHSC) has proposed new restrictions on who can access and provide treatments in a bid to protect people from 'rogue operators' with no medical training who often provide 'invasive' procedures in homes, hotels and pop-up clinics. The move should also reduce the cost imposed upon the NHS to fix botched procedures, DHSC added. Tim Mitchell, president of the Royal College of Surgeons of England, hailed the proposals as an 'important first step forward for patient safety.' Health minister Karin Smyth said: 'The cosmetics industry has been plagued by a Wild West of dodgy practitioners and procedures. 'There are countless horror stories of cosmetic cowboys causing serious, catastrophic damage.' She said the government would take action too 'root out cowboys' and support 'honest and competent practitioners.' 'This isn't about stopping anyone from getting treatments – it's about preventing rogue operators from exploiting people at the expense of their safety and keeping people safe,' Ms Smyth added. 'We're giving them peace of mind and reducing the cost to the NHS of fixing botched procedures.' The government's proposals include: Only allowing healthy workers who are 'suitably qualified' to be able to deliver high-risk procedures such as (BBLs) Ensuring providers are regulated by the health regulator, the Care Quality Commission. Slapping sanctions and finanial penalties on those who break rules on high-risk procedures Ensuring clinics offering Botox and fillers are licensed Introducing age restrictions to prevent children from trying to follow 'dangerous beauty trends on social media' The timeline for the introduction and completion of these measures was not stated. But the DHSC said it will launch a consultation next year seeking views on the range of procedures which should be covered in the new restrictions. Last month, the Chartered Trading Standards Institute warned that fat injections, BBLs, Botox and fillers are being offered by untrained people in places such as public toilets. Before the proposed regulations come into force, the government has urged people seeking cosmetic procedures to ask for the provider's qualifications and insurance, and to be wary of 'suspiciously cheap' offers. Health officials launched an investigation after a number of people had reactions to Botox injections earlier this year. Professor David Sines CBE, the chair and registrar of Joint Council for Cosmetic Practitioners (JCCP), said the move will 'protect the public from untrained and inexperienced operators and it will save the NHS a considerable amount of time and money putting right the harm done through botched procedures.' The statement added the need for the new measures had become increasingly clear in recent years with the 'explosion of high street outlets offering high-risk procedures delivered by people with limited clinical knowledge and training.' He warned this has led to long-term health complications and, in some cases, has led to patient deaths. Mr Mitchell suggested the government must go further on liquid Brazilian Butt Lifts, which the RCS said the procedure should only be performed by a Cosmetic Surgery Board-certified surgeon. The surgeon warned that the procedure needs medical oversight to prevent serious complications and said that while the government's plans will improve the regulation of non-surgical interventions, it must also urgently improve the regulation of surgical procedures. Millie Kendall, chief executive of the British Beauty Council, said: 'Any measures that increase protection for the general public and professionalise the industry will help instil confidence as well as helping to prevent the normalisation of horror stories that have become synonymous with our sector.'
Yahoo
2 hours ago
- Yahoo
Tandem Diabetes (NASDAQ:TNDM) Exceeds Q2 Expectations But Stock Drops 17%
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 8.5% year on year to $240.7 million. The company expects the full year's revenue to be around $1 billion, close to analysts' estimates. Its GAAP loss of $0.78 per share was significantly below analysts' consensus estimates. Is now the time to buy Tandem Diabetes? Find out in our full research report. Tandem Diabetes (TNDM) Q2 CY2025 Highlights: Revenue: $240.7 million vs analyst estimates of $237.1 million (8.5% year-on-year growth, 1.5% beat) EPS (GAAP): -$0.78 vs analyst estimates of -$0.39 (significant miss) Adjusted EBITDA: -$1.85 million vs analyst estimates of $2.34 million (-0.8% margin, significant miss) The company reconfirmed its revenue guidance for the full year of $1 billion at the midpoint Operating Margin: -21.5%, down from -13.9% in the same quarter last year Sales Volumes rose 5% year on year, in line with the same quarter last year Market Capitalization: $1.01 billion Company Overview With technology that automatically adjusts insulin delivery based on continuous glucose monitoring data, Tandem Diabetes Care (NASDAQ:TNDM) develops and manufactures automated insulin delivery systems that help people with diabetes manage their blood glucose levels. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Tandem Diabetes grew its sales at an impressive 19.5% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Tandem Diabetes's annualized revenue growth of 12.4% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. Tandem Diabetes also reports its number of pump shipments, which reached 21,000 in the latest quarter. Over the last two years, Tandem Diabetes's pump shipments averaged 2.9% year-on-year growth. Because this number is lower than its revenue growth, we can see the company benefited from price increases. This quarter, Tandem Diabetes reported year-on-year revenue growth of 8.5%, and its $240.7 million of revenue exceeded Wall Street's estimates by 1.5%. Looking ahead, sell-side analysts expect revenue to grow 4.8% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will see some demand headwinds. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Adjusted Operating Margin Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits. Tandem Diabetes's high expenses have contributed to an average adjusted operating margin of negative 7.9% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. Analyzing the trend in its profitability, Tandem Diabetes's adjusted operating margin decreased by 15.6 percentage points over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 1.6 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn't pass those costs onto its customers. Tandem Diabetes's adjusted operating margin was negative 13.2% this quarter. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Tandem Diabetes's earnings losses deepened over the last five years as its EPS dropped 34.2% annually. We tend to steer our readers away from companies with falling EPS, where diminishing earnings could imply changing secular trends and preferences. If the tide turns unexpectedly, Tandem Diabetes's low margin of safety could leave its stock price susceptible to large downswings. In Q2, Tandem Diabetes reported EPS at negative $0.78, down from negative $0.47 in the same quarter last year. This print missed analysts' estimates. Over the next 12 months, Wall Street expects Tandem Diabetes to improve its earnings losses. Analysts forecast its full-year EPS of negative $3.09 will advance to negative $1.00. Key Takeaways from Tandem Diabetes's Q2 Results It was encouraging to see Tandem Diabetes beat analysts' revenue expectations this quarter. On the other hand, its EPS missed and its sales volume fell short of Wall Street's estimates. Overall, this was a softer quarter. The stock traded down 17% to $12 immediately after reporting. Tandem Diabetes may have had a tough quarter, but does that actually create an opportunity to invest right now? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Inicia sesión para acceder a tu cartera de valores
